Opaganib

Last updated
Opaganib
Opaganib (2).svg
Legal status
Legal status
Identifiers
  • 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C23H25ClN2O
Molar mass 380.92 g·mol−1
3D model (JSmol)
  • C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl
  • InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)
  • Key:CAOTVXGYTWCKQE-UHFFFAOYSA-N

Opaganib (ABC294640) is a drug which acts as an inhibitor of the enzyme sphingosine kinase 2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS). [1] It is under development as a potential treatment agent for several different kinds of cancer. [2] [3] Opaganib has also demonstrated antiviral activity against SARS-CoV-2 and has shown a reduction in mortality among patients with moderately severe COVID-19 in a multinational Phase 2/3 clinical trial and also appeared to exhibiting anti-inflammatory effects by reducing levels of IL-6 and TNF-alpha. [1] [4]

References

  1. 1 2 Smith CD, Maines LW, Keller SN, Katz Ben-Yair V, Fathi R, Plasse TF, Levitt ML (2022). "Recent Progress in the Development of Opaganib for the Treatment of Covid-19". Drug Design, Development and Therapy. 16: 2199–2211. doi: 10.2147/DDDT.S367612 . PMC   9288228 . PMID   35855741.
  2. ↑ Camp ER, Patterson LD, Kester M, Voelkel-Johnson C (September 2017). "Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer". Cancer Biology & Therapy. 18 (9): 640–650. doi:10.1080/15384047.2017.1345396. PMC   5663409 . PMID   28686076.
  3. ↑ Lewis CS, Voelkel-Johnson C, Smith CD (2018). "Targeting Sphingosine Kinases for the Treatment of Cancer". Advances in Cancer Research. 140: 295–325. doi:10.1016/bs.acr.2018.04.015. ISBN   9780128142233. PMC   6447312 . PMID   30060814.
  4. ↑ Bergman SJ (31 December 2024). "COVID-19 Treatment: Investigational Drugs and Other Therapies: Introduction, Antiviral Agents, Immunomodulators and Other Investigational Therapies". Medscape. Retrieved 26 January 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.